Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Transcept Pharmaceuticals, Inc. (TSPT) Starts Presentation at 15th Annual BIO CEO & Investor Conference

Transcept Pharmaceuticals is a specialty pharmaceutical company engaged in developing and commercializing proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo (zolpidem tartrate) sublingual tablet C-IV is the company’s first FDA-approved product. Commercialization and development rights for Intermezzo in the U.S. are held by Purdue Pharma. For more information, visit the company’s Web site at

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit

Let us hear your thoughts below:

This entry was posted in BIO Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *